Royalty Pharma acquires Humira revenue from CAT
Royalty Pharma (acquires royalty interests in late-stage and marketed biopharma products) has purchased royalty rights to Abbott Laboratories' rheumatoid arthritis drug Humira (adalimumab) from Cambridge Antibody Technologies (now part of AstraZeneca).
- Large Molecule
- Royalty Sale
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com